89bio (ETNB) said late Monday it launched a public offering of $250 million in common shares or, in lieu of shares, pre-funded warrants to purchase such shares.
The company expects to grant a 30-day overallotment option to the underwriters to acquire up to $37.5 million of additional shares.
89bio plans to use the net proceeds to fund ongoing clinical activities and development of pegozafermin, among others.
The company's shares were down 2% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.